CHEMOTHERAPY OF METASTATIC BREAST-CANCER IN THE ELDERLY - THE PIEDMONT-ONCOLOGY-ASSOCIATION EXPERIENCE

被引:169
作者
CHRISTMAN, K
MUSS, HB
CASE, LD
STANLEY, V
机构
[1] WAKE FOREST UNIV,CTR COMPREHENS CANC,MED CTR BLVD,WINSTON SALEM,NC 27157
[2] PIEDMONT ONCOL ASSOC,WINSTON SALEM,NC
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1992年 / 268卷 / 01期
关键词
D O I
10.1001/jama.268.1.57
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-To determine the effect of age on treatment outcome in women with metastatic breast cancer treated with chemotherapy. Design.-Case-comparison study of patients with metastatic breast cancer treated in five clinical trials of the Piedmont Oncology Association. Setting.-University and private practice physicians participating in the Piedmont Oncology Association clinical tri,als in the southeastern United States. Patients.-Seventy patients 70 years of age or older were compared with 60 patients aged 50 through 69 years and 40 patients less than 50 years of age. All patients were ambulatory or capable of self-care, with adequate hematologic, renal, and hepatic function. Interventions.-Treatment with multidrug chemotherapy regimens. Main Outcome Measures.-Response to treatment, time to disease progression, survival, and toxic effects. Results.-Pretreatment characteristics including race, performance status; disease-free interval, prior therapy, sites of metastatic disease, and number and dominant sites of metastases were similar for the three age groups. The response rates for the younger-than-50, 50-through-69, and 70-or-older age groups were 40%, 31%, and 29%, respectively (P=.53). There were no significant differences in time to disease progression or survival for patients in the three age groups. Estimates for time to progression and survival were 9.1 and 17.9 months, 6.2 and 12.8 months, and 7.2 and 14.2 months, respectively. Toxic effects, dose delivery, and dose delays were also similar for all three age groups. Conclusions.-Women 70 years of age or older who were enrolled in these trials were similar to their younger counterparts in response rates, time to disease progression, survival, and toxic effects. Women in this age group should not be excluded, based on age alone, from clinical trials involving chemotherapy for advanced breast cancer.
引用
收藏
页码:57 / 62
页数:6
相关论文
共 35 条
[1]  
BALDUCCI L, 1989, SEMIN ONCOL, V16, P76
[2]   HEMATOPOIETIC FUNCTION IN THE ELDERLY [J].
BALDWIN, JG .
ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (12) :2544-2546
[3]  
BEGG CB, 1980, CANCER CLIN TRIALS, V3, P369
[4]  
BEGG CB, 1989, CANCER ELDERLY APPRO
[5]   DOSE-RESPONSE EFFECT OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER [J].
BONADONNA, G ;
VALAGUSSA, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (01) :10-15
[6]   CANCER STATISTICS, 1991 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T .
CA-A CANCER JOURNAL FOR CLINICIANS, 1991, 41 (01) :19-36
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]   THE USE OF CHEMOTHERAPY IN METASTATIC BREAST-CANCER [J].
GARBER, JE ;
HENDERSON, IC .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1989, 3 (04) :807-821
[9]   CYCLOPHOSPHAMIDE, METHOTREXATE, AND 5-FLUOROURACIL CHEMOTHERAPY IN WOMEN MORE THAN 65 YEARS OLD WITH ADVANCED BREAST-CANCER - THE ELIMINATION OF AGE TRENDS IN TOXICITY BY USING DOSES BASED ON CREATININE CLEARANCE [J].
GELMAN, RS ;
TAYLOR, SG .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (12) :1404-1413
[10]   PATTERNS OF CARE RELATED TO AGE OF BREAST-CANCER PATIENTS [J].
GREENFIELD, S ;
BLANCO, DM ;
ELASHOFF, RM ;
GANZ, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (20) :2766-2770